查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1386930

癌症基因治疗市场报告：2030 年趋势、预测与竞争分析

Cancer Gene Therapy Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

癌症基因治疗的趋势和预测

预计到 2030 年，全球癌症基因治疗市场将达到 74 亿美元，2024 年至 2030 年年复合成长率为 17.4%。这个市场的主要驱动因素是基因治疗需求的增加、癌症治疗和皮肤病技术发展的进步以及癌症发病率的增加。全球癌症基因治疗市场前景广阔，医院、生物製药、科研机构市场蕴藏商机。

癌症基因治疗市场洞察

Lucintel 预测，由于遏制癌症成长的研发活动增加，基因引导免疫疗法将在预测期内保持最大的市场规模。

在这个市场中，由于癌症发病率不断上升，以及领先的生物製药公司越来越多地采用成分基因治疗解决方案来设计癌症治疗方法。我会的。

由于政府机构对创新疗法的研究经费增加，以及对新疗法的需求不断增长，以解决该地区迅速增加的癌症病例数量，北美在预测期内仍将是最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球癌症基因治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球癌症基因治疗市场趋势（2018-2023）与预测（2024-2030）
  • 按治疗分類的全球癌症基因治疗市场
    • 溶瘤病毒疗法
    • 基因诱导的免疫治疗
    • 基因转移
    • 其他的
  • 按适应症分類的全球癌症基因治疗市场
    • 乳癌
    • 卵巢癌
    • 肝癌
    • 胰臟癌
    • 肺癌
    • 其他的
  • 按最终用途分類的全球癌症基因治疗市场
    • 医院
    • 生物製药公司
    • 调查机构
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球癌症基因治疗市场按地区划分
  • 北美癌症基因治疗市场
  • 欧洲癌症基因治疗市场
  • 亚太地区癌症基因治疗市场
  • 其他区域癌症基因治疗市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球癌症基因治疗市场的治疗成长机会
    • 全球癌症基因治疗市场成长机会（按适应症）
    • 全球癌症基因治疗市场最终用途的成长机会
    • 全球癌症基因治疗市场按地区成长机会
  • 全球癌症基因治疗市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球癌症基因治疗市场的产能
    • 全球癌症基因治疗市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • Abeona Therapeutics
  • Asklepios BioPharmaceutical
  • Altor Bioscience
  • Bluebird bio
  • BioCancell
  • Celgene
  • Elevate Bio
  • GlaxoSmithKline
  • Genelux
  • GenVec
简介目录

Cancer Gene Therapy Trends and Forecast

The future of the global cancer gene therapy market looks promising with opportunities in the hospital, biopharmaceutical company, and research institute markets. The global cancer gene therapy market is expected to reach an estimated $7.4 billion by 2030 with a CAGR of 17.4% from 2024 to 2030. The major drivers for this market are increasing demand for gene therapy, advance technological development in cancer treatment and daignosis, and growing incidence of cancer cases.

A more than 150-page report is developed to help in your business decisions.

Cancer Gene Therapy by Segment

The study includes a forecast for the global cancer gene therapy by therapy, indication, end use, and region.

Cancer Gene Therapy Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • Oncolytic Virotherapy
  • Gene Induced Immunotherapy
  • Gene Transfer
  • Others

Cancer Gene Therapy Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Breast Cancer
  • Ovarian Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Lung Cancer
  • Others

Cancer Gene Therapy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Biopharmaceutical Companies
  • Research Institutes
  • Others

Cancer Gene Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cancer Gene Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer gene therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer gene therapy companies profiled in this report include-

  • Abeona Therapeutics
  • Asklepios Biopharmaceutical
  • Altor Bioscience
  • Bluebird Bio
  • Biocancell
  • Celgene
  • Elevate Bio
  • Glaxosmithkline
  • Genelux
  • Genvec

Cancer Gene Therapy Market Insights

Lucintel forecasts that gene induced immunotherapy will remain the largest sgement over the forecast period due to increasing research & development activities to lower the proliferation of cancer.

Within this market, biopharmaceutical companies will remain the largest segment due to increasing prevelance of cancer and growing adoption of elemental gene therapy solutions by major biopharmaceutical companies for designing cancer treatment regimens.

North America will remain the largest region over the forecast period due to increasing research funding for innovative therapeutics by government entities and the rising demand for novel therapeutics to address the escalating number of cancer cases in the region.

Features of the Global Cancer Gene Therapy Market

Market Size Estimates: Cancer gene therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer gene therapy market size by therapy, indication, end use, and region in terms of value ($B).

Regional Analysis: Cancer gene therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapies, indications, end uses, and regions for the cancer gene therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer gene therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the cancer gene therapy market size?

Answer: The global cancer gene therapy market is expected to reach an estimated $7.4 billion by 2030.

Q.2 What is the growth forecast for cancer gene therapy market?

Answer: The global cancer gene therapy market is expected to grow with a CAGR of 17.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the cancer gene therapy market?

Answer: The major drivers for this market are increasing demand for gene therapy, advance technological development in cancer treatment and daignosis, and growing incidence of cancer cases.

Q4. What are the major segments for cancer gene therapy market?

Answer: The future of the cancer gene therapy market looks promising with opportunities in the hospital, biopharmaceutical company, and research institute markets.

Q5. Who are the key cancer gene therapy market companies?

Answer: Some of the key cancer gene therapy companies are as follows:

  • Abeona Therapeutics
  • Asklepios Biopharmaceutical
  • Altor Bioscience
  • Bluebird Bio
  • Biocancell
  • Celgene
  • Elevate Bio
  • Glaxosmithkline
  • Genelux
  • Genvec

Q6. Which cancer gene therapy market segment will be the largest in future?

Answer: Lucintel forecasts that gene induced immunotherapy will remain the largest sgement over the forecast period due to increasing research & development activities to lower the proliferation of cancer.

Q7. In cancer gene therapy market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing research funding for innovative therapeutics by government entities and the rising demand for novel therapeutics to address the escalating number of cancer cases in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cancer gene therapy market by therapy (oncolytic virotherapy, gene induced immunotherapy, gene transfer, and others), indication (breast cancer, ovarian cancer, liver cancer, pancreatic cancer, lung cancer, and others), end use (hospitals, biopharmaceutical companies, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Gene Therapy Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cancer Gene Therapy Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cancer Gene Therapy Market by Therapy
    • 3.3.1: Oncolytic Virotherapy
    • 3.3.2: Gene Induced Immunotherapy
    • 3.3.3: Gene Transfer
    • 3.3.4: Others
  • 3.4: Global Cancer Gene Therapy Market by Indication
    • 3.4.1: Breast Cancer
    • 3.4.2: Ovarian Cancer
    • 3.4.3: Liver Cancer
    • 3.4.4: Pancreatic Cancer
    • 3.4.5: Lung Cancer
    • 3.4.6: Others
  • 3.5: Global Cancer Gene Therapy Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Biopharmaceutical companies
    • 3.5.3: Research Institutes
    • 3.5.4: others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cancer Gene Therapy Market by Region
  • 4.2: North American Cancer Gene Therapy Market
    • 4.2.2: North American Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others
  • 4.3: European Cancer Gene Therapy Market
    • 4.3.1: European Cancer Gene Therapy Market by Therapy: Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others
    • 4.3.2: European Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others
  • 4.4: APAC Cancer Gene Therapy Market
    • 4.4.1: APAC Cancer Gene Therapy Market by Therapy: Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others
    • 4.4.2: APAC Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others
  • 4.5: ROW Cancer Gene Therapy Market
    • 4.5.1: ROW Cancer Gene Therapy Market by Therapy: Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others
    • 4.5.2: ROW Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cancer Gene Therapy Market by Therapy
    • 6.1.2: Growth Opportunities for the Global Cancer Gene Therapy Market by Indication
    • 6.1.3: Growth Opportunities for the Global Cancer Gene Therapy Market by End Use
    • 6.1.4: Growth Opportunities for the Global Cancer Gene Therapy Market by Region
  • 6.2: Emerging Trends in the Global Cancer Gene Therapy Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cancer Gene Therapy Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Gene Therapy Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Abeona Therapeutics
  • 7.2: Asklepios BioPharmaceutical
  • 7.3: Altor Bioscience
  • 7.4: Bluebird bio
  • 7.5: BioCancell
  • 7.6: Celgene
  • 7.7: Elevate Bio
  • 7.8: GlaxoSmithKline
  • 7.9: Genelux
  • 7.10: GenVec